# TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

> **NCT04887506** · PHASE3 · COMPLETED · sponsor: **Tavanta Therapeutics** · enrollment: 107 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Metastatic Castration-sensitive Prostate Cancer
- Metastatic Prostate Cancer

## Interventions

- **DRUG:** TAVT-45
- **DRUG:** Zytiga
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04887506
- **Lead sponsor:** Tavanta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-05
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-20
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2024-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04887506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04887506, "TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04887506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*